DeviceTalks

DeviceTalks

The DeviceTalks Podcast Network delivers news, insights and commentary from Medtech industry leaders. Our podcasts will inspire medtech professionals to create better medtech devices and companies. Explore the DeviceTalks Podcast Network, home to more than 8 podcasts: • AbbottTalks • AI Meets Life Sci • Boston Scientific Talks • DeviceTalks Weekly • IntuitiveTalks • MedtechWOMEN Talks • MedtronicTalks • Ortho Innovation Talks: Zimmer Biomet • StrykerTalks read less
TechnologyTechnology

Episodes

How do I take an approved medical device to market? with YJ Oh, Edwards Lifesciences
3d ago
How do I take an approved medical device to market? with YJ Oh, Edwards Lifesciences
In the final episode of MedtechWOMEN Talks season one, we are joined by YJ Oh, SVP US Sales, Marketing and Commercial Operations at Edwards Lifesciences, who takes us through the intricate process of medical device commercialization. Starting with her unique entry into the medtech industry, YJ shares her comprehensive journey from sales to global marketing, emphasizing the significant role of upstream marketing in shaping product development and downstream efforts in executing commercial strategies. In the discussion, YJ highlights the criticality of understanding market needs right from the inception of a product idea, ensuring that every development phase aligns with customer insights and real-world applicability. She provides a glimpse into the key collaborations across various departments and touches on the essential feedback mechanisms in place, ensuring devices meet the stringent requirements and expectations set forth by both regulatory bodies and the end-users, primarily physicians. Her insights extend into the strategic considerations for global market penetration, discussing how different regulatory landscapes affect the accessibility and success of medical devices across borders. TL;DR – Key Takeaways: - The integration of market insights from the beginning is crucial for successful medical device commercialization. - Collaborative efforts across various functions are vital to address the comprehensive demands of product development. - Strategic global considerations are imperative to navigate varying regulatory and market conditions effectively. Thank you to our season one sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical! https://aptyx.com/ https://catalyzehealthcare.com/ https://confluentmedical.com/ https://www.cretex.com/ Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for listening to MedtechWOMEN Talks!
How does the internal medical device development process work at large medtechs?
Mar 19 2024
How does the internal medical device development process work at large medtechs?
In the latest episode of MedtechWOMEN Talks, Rebecca Whitney, SVP, Global Spine President, ZimVie dives deep into what it takes to bring innovative medical solutions to market in a large medtech OEM, weighing the benefits of internal product development against strategic external partnerships. ​ The episode shines a light on the diligent process behind medical device product development, taking into consideration global market nuances, regulatory challenges, and the balance between in-house innovations and external collaborations. Whitney underscores the value of rigorous review stages, which sometimes require difficult decisions like ceasing investment in long-term, costly projects. Key Takeaways: - Tough decisions, like halting a project, are necessary for the betterment of patient care and resource allocation. - Product development incorporates feedback from patients, surgeons, and salesforces to ensure that solutions are practical and market-appropriate. - Strategic external partnerships can optimize development by leveraging outside expertise, allowing large medtechs like ZimVie to focus on their core strengths. Thank you to our season one sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical! Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for listening to MedtechWOMEN Talks!
Abbott electrophysiology leaders highlight current portfolio, give glimpse of potential PFA device
Mar 12 2024
Abbott electrophysiology leaders highlight current portfolio, give glimpse of potential PFA device
In the latest episode of AbbottTalks, Abbott Cardiovascular's leaders, Christopher Piorkowski, MD, DVP and Chief Medical Officer of Electrophysiology, and Dan Kaiser, Divisional VP Product Development, Electrophysiology, delve into the vast landscape of electrophysiology and the comprehensive approach Abbott is taking towards atrial fibrillation (AFib) treatment. The conversation highlights a potentially innovative pulsed field ablation (PFA) technology and Abbott's broader AFib portfolio, showcasing a commitment to revolutionizing cardiac arrhythmia management. While the Volt™ Pulsed Field Ablation System could represent a significant leap forward with its unique capabilities for creating precise and tissue-selective lesions, Piorkowski and Kaiser emphasize the diversity and depth of solutions Abbott is developing. This includes advancements in diagnostic tools, patient monitoring, and a range of therapeutic approaches designed to offer customized and effective treatment pathways for individuals with AFib. By focusing on a holistic view of patient care, they discuss how Abbott aims to improve clinical outcomes through technological innovation and enhance patients' quality of life by making treatments more accessible, reducing procedure times, and addressing the broad spectrum of needs within the electrophysiology community. With ongoing clinical trials and research, Abbott is positioned at the forefront of addressing the unmet needs in AFib management, underlining the company's commitment to continuous innovation and patient-centered care. Thank you to Cretex Medical for sponsoring this episode of AbbottTalks. For more information on how Cretex Medical works with medical device companies, visit www.cretexmedical.com. Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.
ZB’s Goyal Explains How Passion for Solving Ortho Challenges Put Him at the Helm of ZB’s R&D Engine
Mar 6 2024
ZB’s Goyal Explains How Passion for Solving Ortho Challenges Put Him at the Helm of ZB’s R&D Engine
In this episode of Ortho Innovation Talks, Nitin Goyal, MD, chief science, technology and innovation officer at Zimmer Biomet (ZB) shares his journey from the OR to the medtech industry. Dr. Goyal oversees ZB’s global innovation, medical education, clinical affairs, and reimbursement strategy. He tells host Tom Salemi about his passion for building solutions to address clinical challenges and improve the surgical experience. Goyal’s own innovations landed him leadership positions at managed care powerhouse, UnitedHealthcare, followed by medtech giant, ZB. Goyal describes how his pursuit of “making an outsized impact” on orthopedic care brought him to ZB, where he leads the global innovation, medical education, and clinical affairs functions. In this talk, he’ll discuss how ZB incorporates smart implants that track and report mobility data, to big data analytics that guide clinical decision-making throughout the episode of care. Goyal explains why he believes we’re at an inflection point in orthopedics and how ZB intends to lead the way. Thank you to our season one sponsors, Millstone Medical and AcuityMD, for supporting this podcast. To learn more about our episode sponsor, Millstone Medical, please visit http://millstonemedical.com. Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for listening to the Ortho Innovation Talks podcast!
Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials
Feb 13 2024
Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials
This episode of AI Meets Life Sci offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company. Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says. Join us for the next episode of AI Meets Life Sci, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic. Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support. catalyzehealthcare.com smarttrak.com Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode. WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/ Thank you for supporting AI Meets Life Sci!
How do I get a medical device in front of the right people? with Nicole Osmer
Feb 6 2024
How do I get a medical device in front of the right people? with Nicole Osmer
In the latest episode of MedtechWOMEN Talks, Nicole Osmer, Founder & CEO at Health+Commerce, shares her expertise on the role of branding, media relations, and public relations in the medical device product development cycle from the perspective of “The Publicist.” In the episode, Osmer shares the significance of establishing a strong brand right from a company's inception. Attention to detail in messaging, brand presence, and even the subtleties like an area code on a contact page are pivotal. A central theme revolves around structuring communication effectively through traditional and emerging media channels to make significant market impacts. Osmer's insights on press releases, direct media outreach, and the role of digital platforms offer valuable takeaways on modern medtech marketing. The episode covers not only the 'what' but also the 'how' of successful medtech communications. TL;DR – Key takeaways: 1. Establishing a strong brand from the early stages and maintaining it throughout the lifecycle of a medtech company is crucial for lasting success. 2. Clear, concise messaging and being prepared for media opportunities with key story elements is essential in PR and branding. 3. Press releases remain a relevant tool for communication, especially when they are concise, impactful, and include a compelling headline. 4. Collaboration across various company functions such as marketing, clinical teams, and investor relations is integral to a coherent communication strategy. Thank you to our sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical for providing vital support. https://aptyx.com/  https://catalyzehealthcare.com/  https://confluentmedical.com/ https://www.cretexmedical.com/ Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.
Medtronic’s Jason Weidman recalls the long, bumpy road to getting FDA approval for Symplicity Spiral
Feb 2 2024
Medtronic’s Jason Weidman recalls the long, bumpy road to getting FDA approval for Symplicity Spiral
This week’s DeviceTalks Weekly is a bit of a retrospective on Medtronic’s Symplicity Spiral Renal Denervation System. It obviously ends on a happy note, and we’ll catch up with Jason Weidman, SVP and president of Medtronic’s Coronary and Renal Denervation business in an interview conducted in January. Thank you to AcuityMD for sponsoring this podcast. www.acuityMD.com. Weidman talked with Co-Host Tom Salemi last month to recap a bit of a history of the program including the dramatic – and successful – conclustion at the FDA. We also draw from an earlier interview Weidman gave to our MedtronicTalks Podcast in 2021. Together, these clips and interviews reflect the time and dedication that ambitious medtech programs require. In the current interview, Weidman also give a glimpse of renal denervation’s future. Other resources Medtech Talk Podcast - https://medtechmvp.com/media/medtech-talk-podcast/Mark-Gelfand-Howard-Levin-Discuss-Coridea-Ardian-and-How-They-re-Innovating-Medtech-Innovation 2021 MedtronicTalks Podcast with Jason Weidman - https://www.devicetalks.com/weidman-talks-us-through-the-long-road-to-ge Co-Host Chris Newmarker, executive editor of MassDevice, also discusses his new article – 10 Surgical Robotic Companies that You Need to Know. https://www.massdevice.com/10-surgical-robotics-companies-you-need-to-know-2024/ Thank you for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast player.